ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1454

B Cell-specific TLR7 Regulates Lupus in TLR9 Deficient Mice
Abstract Number: 1060

B-cell-rich Inflammatory Myopathies in Adults: Striking Association with Connective Tissue Diseases
Abstract Number: 0996

Bacteria-Derived Indole Drives Autoimmune Arthritis by Altering B Cell Glycosylation of Autoantibodies
Abstract Number: 0778

Bacterial Families Lachnospiraceae/Ruminococcaceae Are Immunologically Targeted in Individuals At-risk for RA and a Specific Strain Is Arthritogenic in Monocultured Gnotobiotic Mice
Abstract Number: 1228

Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials
Abstract Number: 1135

Barriers to Influenza Vaccination in Patients at a Tertiary Care Rheumatology Clinic
Abstract Number: 1832

Barriers to Medication Adherence and Degree of Nonadherence in a Systemic Lupus Erythematosus Outpatient Population
Abstract Number: 0587

Barriers to Rheumatologic Care and Antimalarial Refills Among a Cohort of Patients with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Abstract Number: 1362

BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study
Abstract Number: 0390

Baseline Characteristics of Systemic Sclerosis (SSc) Patients with Restrictive Lung Disease in a Multi-Center United States Based Longitudinal Registry
Abstract Number: 0698

Baseline Factors Are Not Associated with Rehabilitation Dose over Six Months Among Adults with RA
Abstract Number: 2016

Baseline Serum Biomarker Levels Predict Spinal Radiographic Progression in Ankylosing Spondylitis Patients on TNF Inhibitor Therapy
Abstract Number: 1762

Benefit and Risk Profiles of Janus Kinase Inhibitors Approved in the US for the Treatment of RA
Abstract Number: 1487

Biclustering Reveals Potential Knee Osteoarthritis Phenotypes in Exploratory Analyses: Data from the Osteoarthritis Initiative
Abstract Number: 0986

BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
Abstract Number: 1653

Bilateral vs Unilateral Total Knee Arthroplasty: Racial Variation in Utilization and In-Hospital Major Complication Rates
Abstract Number: 0356

Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
Abstract Number: 1364

Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study
Abstract Number: 1352

Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension
Abstract Number: 0906

Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
Abstract Number: 0127

Biochemical Algorithm to Identify Individuals with ALPL Variants Between Subjects with Persistent Hypophosphatasaemia
Abstract Number: 1045

Biological therapy in atypical optic neuritis refractory to conventional treatment. A multicenter study with 19 patients.
Abstract Number: 0348

Biologics History and Sex Are Linked to Golimumab Discontinuation in Axial Spondyloarthritis: A Sub-Analysis of the Post-Registration GO-Practice Study
Abstract Number: 1834

Biomarker Analysis of IFN-I Modulation in JNJ-839: First-in-Human Study for Systemic Lupus Erythematosus
Abstract Number: 1197

Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review
Abstract Number: 1831

Biomarkers Linked to Anti-IFN-I and Ustekinumab Suggest Distinct Mechanism of Action in Systemic Lupus Erythematosus
Abstract Number: 0859

Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
Abstract Number: 1522

Biomarkers of Hemodynamic Severity of Systemic-Sclerosis Associated Pulmonary Arterial Hypertension by Serum Proteome Analysis
Abstract Number: 1763

Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 1229

Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
Abstract Number: 1548

Blood Pressure, BMI and Sex Affect Optical Spectral Transmission Imaging Measurements of the Hands
Abstract Number: 1508

Blood-Brain Barrier Leakage in Systemic Lupus Erythematosus Is Associated with Gray Matter Loss and Cognitive Impairment
Abstract Number: 1755

Body Mass Index Trajectory and Variability in Rheumatoid Arthritis
Abstract Number: 0104

Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis
Abstract Number: 1590

Bone Health in ANCA – Associated Vasculitis Patients
Abstract Number: 0102

Bone Health in Patients with Psoriatic Arthritis in the National Swiss Cohort: A Cross-sectional Study
Abstract Number: 1118

Bone Marrow Lesion Scores in Patients with Knee Osteoarthritis Undergoing Tibial Osteotomy: Reliability and Concurrent Validity of the Knee Inflammation MRI Scoring System (KIMRISS)
Abstract Number: 1336

Bone Mineral Density, Trabecular Bone Score and Proximal Femur 3D-DXA Analysis in Psoriatic Diseases
Abstract Number: 0978

Border-associated Macrophages Drive Recruitment of Immune Cells into the Choroid Plexus in Mice with Neuropsychiatric Lupus
Abstract Number: 1747

Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebo-controlled Trial (PreCePRA)
Abstract Number: 1042

Building LSU Uveitis Registry ( BLUR ) Study – a Review of an Academic Rheumatology Center’s Experience and Approach to Uveitis

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].